⛔️Press release⛔️

Phase 2b Study of Oral Omadacycline M. abscessus Pulmonary Disease

➡️ 1st placebo RCT M.abscessus

➡️ Sx-based endpoints = 👍

➡️ Microbiologic endpoints = higher conversion (-) culture, no R

➡️ 12w, omadacycline safe & well-tolerated

#IDsky

https://www.globenewswire.com/news-release/2024/11/08/2977671/0/en/Paratek-Pharmaceuticals-Announces-Positive-Top-Line-Data-from-Phase-2b-Study-of-Oral-Omadacycline-OMC-in-Nontuberculous-Mycobacterial-NTM-Abscessus-Pulmonary-Disease.html

Comments